STOCKS TELEGRAPH

Tag: China Pharma Holdings Inc.

  • China Pharma Holdings, Inc. (CPHI) Stock Soaring in Premarket Despite no Reason

    China Pharma Holdings, Inc. (CPHI) Stock Soaring in Premarket Despite no Reason

    China Pharma Holdings, Inc. (CPHI) is a biopharmaceutical firm focused on the development, manufacturing, and marketing of products for treating cardiovascular, CNS, and digestive disorders. The products of the company include cerebroprotein hydrolysate for memory decline, gastrodin for loss of concentration, propyl gallate for cerebral thrombosis, bumetanide for edema, and candesartan for hypertension.

    The price of CPHI stock during the regular trading on February 3, 2022, was $0.49 with a 17.2% gain. At last check in the premarket on February 4, 2022, the stock further jumped by 10.1%.

    CPHI: Key Financials

    On November 12, 2021, CPHI released its financial results for the quarter ended September 30, 2021. Some of the key features are discussed below.

    Revenue

    Revenue recorded in Q3 2021 was $2.0 million compared to $2.4 million in the same period of 2020. A decline of 17.6% was observed in the revenue over the period of the year. The decline in the revenue was the result of the extension of the national centralized drug acquisitions scope and the associated price drop. The financial analysts also observed that the company missed the estimated revenue target by $307.2 thousand.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $0.8 million or $0.02 compared to $1.0 million or $0.02 in the same quarter of 2020. The net loss was reduced over the period of the year due to a reduction in selling costs in 2021. The company missed the estimated EPS by $0.04/

    CPHI: CEO Comments

    Speaking at the occasion, CPHI CEO Zhilin Li stated that the company focused on the consistency assessment of its registered products in the quarter. He further added that the company’s lead product Candesartan had passed the consistency assessment test. The company had submitted the application resources to the National Medical Products Administration.

    Conclusion

    CPHI stock is 45% down the past six months due to economic restraints caused as a result of the pandemic. The company’s stock is in a good position in the recent premarket due to uncertain factors as no official statement, SEC filing, or forthcoming event is listed on the company’s website.

  • Top 15 Healthcare Stocks You Should Add To Your Bucket

    The global generics drug market continues to grow with the increasing demand for more medication. Drug manufacturers are continuously striving to meet the need for more generic drugs. This industry is an opportunity-rich industry. Efficient and inexpensive drugs are often needed. The drug manufacturing industry has seen a huge transformation over the last two decades.

    This industry-main challenge is to provide the drug at lower prices than branded drugs. Drug manufacturers and Specialty Generic Industry will face more pressure in the coming years to lower the prices of drugs.  The industry is expected to grow significantly over the next decade. Check out the leading companies in drug manufacturers- specialty generic industry to see how these are addressing the needs of their customers:

    Sundial Growers Inc. (NASDAQ: SNDL)

    Sundial Growers Inc. (NASDAQ: SNDL) shares were trading down -6.32% at $0.17 at the time of writing on Wednesday. Sundial Growers Inc. (NASDAQ: SNDL) share price went from a low point around $0.17 to briefly over $4.12 in the past 52 weeks, though shares have since pulled back to $0.17. SNDL market cap has remained high, hitting $32.59M at the time of writing, giving it a price-to-sales ratio of more than 0.

    Sundial Growers Inc. (SNDL) has revealed earlier that it has expanded the Palmetto brand presence across Canada. If we look at the recent analyst rating SNDL, CIBC upgraded coverage on SNDL shares with a Neutral rating.

    Teligent Inc. (NASDAQ: TLGT)

    Teligent Inc. (NASDAQ: TLGT) last closed at $1.04, in a 52-week range of $0.65 to $8.00. The Schall Law Firm has earlier revealed that it is investigating claims on behalf of investors in Teligent, Inc. for potential breaches of fiduciary duty on the part of its directors and management. Teligent Inc.’s market cap has remained high, hitting $5.68 Million at the time of writing.

    Zomedica Corp. (AMEX: ZOM)

    Zomedica Corp. (AMEX: ZOM) stock drop by -3.82% to $0.08. Zomedica Corp. (ZOM) revealed that it has changed its legal name to Zomedica Corp. The Company’s stock trading symbol will remain as ZOM on the NYSE American and the shares will start trading under the new name effective on October 5, 2020.

    Aurora Cannabis Inc. (NYSE: ACB)

    Aurora Cannabis Inc. (NYSE: ACB) shares headed rising, higher as much as 6.36%. The most recent rating by Jefferies, on September 21, 2020, is at a Hold. Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of Aurora Cannabis Inc. (ACB) shareholders.

    Tilray Inc. (NASDAQ: TLRY)

    Tilray Inc. (NASDAQ: TLRY) rose 2.96% after gaining more than $0.19 on Wednesday. Tilray Inc. (TLRY) earlier revealed that its wholly-owned subsidiary, High Park Holdings Ltd. has introduced the newest addition to its cannabis-infused edible product line: Chowie Wowie Gummies, which are now available in select provinces across Canada.

    Neos Therapeutics Inc. (NASDAQ: NEOS)

    Neos Therapeutics Inc. (NASDAQ: NEOS) last closed at $0.86, in a 52-week range of $0.45 to $1.98. Neos Therapeutics Inc. (NEOS) has reported that its sales in quarter two reached $13.13 million. However, earnings dropped by 51.17%, resulting in a loss of $2.88 million. In Q1, Neos Therapeutics brought in $14.49 million in sales but lost $5.89 million in earnings.

    Teva Pharmaceutical Industries Limited (NYSE: TEVA)

    Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares headed rising, higher as much as 3.72%. The most recent rating by Barclays, on August 06, 2020, is at an Equal-weight. Pomerantz LLP revealed that a class action lawsuit has been lodged against Teva Pharmaceuticals Industries Limited and certain of its officers.

    Elanco Animal Health Incorporated (NYSE: ELAN)

    Elanco Animal Health Incorporated (NYSE: ELAN) shares headed falling, lower as much as -2.56%. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Overweight. Elanco Animal Health Incorporated (ELAN) has revealed that it has got a notification of an unsolicited ‘mini-tender”‘ offer by TRC Capital Investment Corporation to buy up to 4,000,000 shares of Elanco common stock, representing approximately 1.00% of the outstanding shares of Elanco common stock.

    HEXO Corp. (NYSE: HEXO)

    HEXO Corp. (NYSE: HEXO) fall -0.91% after losing more than -$0.01 on Wednesday. HEXO Corp. (HEXO) has earlier disclosed that it has appointed Trent MacDonald to its executive leadership team in the acting role of Chief Financial Officer, effective October 10, 2020. Its market cap has remained high, hitting $365.78 million at the time of writing.

    Bausch Health Companies Inc. (NYSE: BHC)

    Bausch Health Companies Inc. (BHC) last closed at $17.57, in a 52-week range of $11.15 to $31.97. Analysts have a consensus price target of $26.76. Bausch Health Companies Inc. (BHC) and Lomb, its leading global eye health business, along with BHVI, revealed previously that an affiliate of Bausch Health has bought an exclusive license for a myopia control contact lens design developed by BHVI.

    Endo International plc (NASDAQ: ENDP)

    Endo International plc (NASDAQ: ENDP) stock drop by -5.69% to $5.47. The most recent rating by Goldman, on July 27, 2020, is at a Sell. Endo International plc (ENDP) revealed that it has decided to buy all of the outstanding shares of BioSpecifics Technologies Corp. for $88.50 in cash per share or an estimated enterprise value of approximately $540 million at the expected time of deal closure.

    China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

    China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) stock soar by 9.65% to $0.31. China SXT Pharmaceuticals Inc. (SXTC) share has fluctuated between the 52-weeks low of $0.22 and 52-weeks high of $1.56 during the trading session of Wednesday. It has moved up 40.64% from its 52-weeks low and moved down -79.97% from its 52-weeks high.

    Canopy Growth Corporation (NYSE: CGC)

    Canopy Growth Corporation (NYSE: CGC) rose 3.23% after gaining more than $0.61 on Wednesday. Canopy Growth Corporation (CGC) share price went from a low point around $9.00 to briefly over $25.97 in the past 52 weeks, though shares have since pulled back to $19.49. CGC market cap has remained high, hitting $7.24 billion at the time of writing.

    Aphria Inc. (NASDAQ: APHA)

    Aphria Inc. (NASDAQ: APHA) last closed at $4.68, in a 52-week range of $1.95 to $6.44. Aphria Inc. (APHA) has moved up 140.00% from its 52-weeks low and moved down -27.33% from its 52-weeks high. Its market cap has remained high, hitting $1.25 billion at the time of writing.

    China Pharma Holdings Inc. (CPHI)

    China Pharma Holdings Inc. (CPHI) stock soar by 6.86% to $0.50. The most recent rating by Rodman & Renshaw, on January 08, 2010, is at an Mkt outperform. China Pharma Holdings Inc. (CPHI) has moved up 134.13% from its 52-weeks low and moved down -64.53% from its 52-weeks high. Its market cap has remained high, hitting $22.72 million at the time of writing.